Palisade Bio (PALI) Operating Margin (2011 - 2026)

Palisade Bio (PALI) posted quarterly Operating Margin of 1011.6% for Q1 2023, up 99.22% quarter-over-quarter from 129800.0% in Q4 2020.

Palisade Bio (PALI) Operating Margin (2011 - 2026) Analysis & Trends

Palisade Bio (PALI) has reported Operating Margin for 11 consecutive years, with 1011.6% the latest figure, recorded in Q1 2023.

In Q1 2023, Operating Margin changed N/A year-over-year to 1011.6%; the TTM figure through Dec 2023 stood at 5228.0% (changed N/A YoY), while the FY2023 annual figure was 5228.0%, changed N/A from the prior year.
Operating Margin advanced to 1011.6% in Q1 2023 per PALI's latest filing, from 129800.0% in the prior quarter.
Across five years, Operating Margin topped out at 1011.6% in Q1 2023 and bottomed at 129800.0% in Q4 2020.
Historically, Operating Margin has averaged 66998.9% across 3 years, with a median of 73640.0% in 2020.
On a YoY basis, Operating Margin climbed as much as 6519841 bps in 2020 and fell as far as 4933824 bps in 2020.
Palisade Bio's Operating Margin stood at 85302.92% in 2019, then sank by 52 bps to 129800.0% in 2020, then jumped by 99 bps to 1011.6% in 2023.
Business Quant data shows PALI's Operating Margin at 1011.6% in Q1 2023, 129800.0% in Q4 2020, and 72640.0% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-105.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Palisade Bio	372.94 Mn	247.74 Mn	-	-2,339.60%

Download Data